Concepedia
Statistics
Publications
21
Citations
2.9K
H-Index
19
Active since
1990
Affiliations
Exelixis (United States)(Current)
University of Konstanz
University of California, San Francisco
Washington University in St. Louis
Rigshospitalet
Stefan Engst is an author at Exelixis (United States) specializing in pharmacology, life sciences, and enzymology.
Publications per year
1990–2017
Cabozantinib (XL184), a Novel MET and VEGFR2 Inhibitor, Simultaneously Suppresses Metastasis, Angiogenesis, and Tumor Growth
F. Michael Yakes, Jason Chen, Jenny Tan et al. · Molecular Cancer Therapeutics · 2011 · 1.3K citations · Full text
Medicine, Oncology, Pharmacology +17
Inhibition of Tumor Cell Growth, Invasion, and Metastasis by EXEL-2880 (XL880, GSK1363089), a Novel Inhibitor of HGF and VEGF Receptor Tyrosine Kinases
Fawn Qian, Stefan Engst, Peiwen Yu et al. · Cancer Research · 2009 · 338 citations
Intermittent Administration of MEK Inhibitor GDC-0973 plus PI3K Inhibitor GDC-0941 Triggers Robust Apoptosis and Tumor Growth Inhibition
Klaus P. Hoeflich, Mark Merchant, Christine Orr et al. · Cancer Research · 2011 · 244 citations · Full text
Novel Carboxamide-Based Allosteric MEK Inhibitors: Discovery and Optimization Efforts toward XL518 (GDC-0973)
Kenneth D. Rice, Naing Aay, Neel K. Anand et al. · ACS Medicinal Chemistry Letters · 2012 · 168 citations · Full text
Medicine, Oncology, Pharmacology +14
<i>In Vitro</i> and <i>In Vivo</i> Activity of Cabozantinib (XL184), an Inhibitor of RET, MET, and VEGFR2, in a Model of Medullary Thyroid Cancer
Frauke Bentzien, Marcus Zuzow, Nathan Heald et al. · Thyroid · 2013 · 130 citations · Full text
Medicine, Oncology, Pharmacology +16
1–5 of 21